NEX-I is a pioneering team in the realm of immuno-oncology, taking innovative footsteps to challenge and transform current cancer treatment methods. At the heart of its cutting-edge strategy is ONCOKINE screening technology, an unprecedented target discovery program developed to overcome the inherent resistance of cancer cells to existing therapies. NEX-I is reshaping the landscape of cancer treatment by spearheading innovative solutions in the persistent battle against cancer.